- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00454207
Open Label Study of Sildenafil in Patients With Pulmonary Arterial Hypertension
January 28, 2021 updated by: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
A Phase 3, Multi-Center, Open-Label Study to Assess Safety and Efficacy of Sildenafil Citrate 20 mg TID in Subjects With Pulmonary Arterial Hypertension
To assess the safety of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1 and 2) To assess the efficacy after 12 weeks of treatment of sildenafil 20 mg TID orally given to Japanese pulmonary arterial hypertension patients (Part 1)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
44
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- Pfizer Investigational Site
-
-
Chiba
-
Chiba-shi, Chiba, Japan
- Pfizer Investigational Site
-
-
Ishikawa
-
Kanazawa, Ishikawa, Japan
- Pfizer Investigational Site
-
-
Mie
-
Tsu-shi, Mie, Japan
- Pfizer Investigational Site
-
-
Okayama
-
Okayama City, Okayama, Japan
- Pfizer Investigational Site
-
-
Shizuoka
-
Hamamatsu-shi, Shizuoka, Japan
- Pfizer Investigational Site
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Shinjuku-ku, Tokyo, Japan
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects aged 16 and over, and classified as having pulmonary arterial hypertension
- Subjects who meet the following conditions on right heart catheterization at screening or baseline: mean pulmonary arterial pressure of ≥ 25mmHg and pulmonary capillary wedge pressure of ≤ 15mmHg at rest
- Subjects whose baseline 6-Minute Walk test distance is >100 m and <450 m
Exclusion Criteria:
- Significant Hepatic and/or renal disorder
- Subjects with known hereditary degenerative retinal disorders (such as retinitis pigmentosa) or history of non-arteritic ischemic optic neuropathy (NAION)
- Subjects who are currently receiving nitrates or nitric oxide donors in any form, ritonavir, ketoconazole and itraconazole
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: sildenafil citrate (UK-92,480)
sildenafil citrate 20 mg TID
|
sildenafil citrate (UK-92,480)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:6-minute walk distance at Week 12 minus 6-minute walk distance at baseline.
The 6-minute walk distance:total distance walked during the 6-minute walk test.
|
Baseline, Week 12
|
Change in the Mean Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Mean pulmonary arterial pressure at Week 12 minus mean pulmonary arterial pressure at baseline.
|
Baseline, Week 12
|
Change in the Pulmonary Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Pulmonary vascular resistance at Week 12 minus pulmonary vascular resistance at baseline
|
Baseline, Week 12
|
Change in the Cardiac Output From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, week 12
|
Change:Cardiac output at Week 12 minus cardiac output at baseline
|
Baseline, week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the 6-minute Walk Distance From Baseline at Week 8 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 8
|
Change:6-minute walk distance at Week 8 minus 6-minute walk distance at baseline. The 6-minute walk distance:Total distance walked during the 6- minute walk test. |
Baseline, Week 8
|
Change in the Systolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Systolic pulmonary arterial pressure at Week 12 minus Systolic pulmonary arterial pressure at baseline.
|
Baseline, Week 12
|
Change in the Diastolic Pulmonary Arterial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Diastolic pulmonary arterial pressure at Week 12 minus diastolic pulmonary arterial pressure at baseline.
|
Baseline, Week 12
|
Change in the Systolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Systolic systemic blood pressure at Week 12 minus systolic systemic blood pressure at baseline.
|
Baseline, Week 12
|
Change in the Diastolic Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Diastolic systemic blood pressure at Week 12 minus diastolic systemic blood pressure at baseline.
|
Baseline, Week 12
|
Change in the Mean Systemic Blood Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Mean systemic blood pressure:diastolic blood pressure+(systolic blood pressure-diastolic blood pressure)/3. Change:Mean systemic blood pressure at Week 12 minus mean systemic blood pressure at baseline. |
Baseline, Week 12
|
Change in the Pulmonary Capillary Wedge Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Pulmonary capillary wedge pressure at Week 12 minus pulmonary capillary wedge pressure at baseline.
|
Baseline, Week 12
|
Change in the Right Atrial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Right atrial pressure at Week 12 minus right atrial pressure at baseline.
|
Baseline, Week 12
|
Change in the Cardiac Index From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Cardiac index at Week 12 minus cardiac index at baseline.
|
Baseline, Week 12
|
Change in the Heart Rate From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Heart rate at Week 12 minus heart rate at baseline.
|
Baseline, Week 12
|
Change in the Pulmonary Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Pulmonary vascular resistance index at Week 12 minus pulmonary vascular resistance index at baseline.
|
Baseline, Week 12
|
Change in the Systemic Vascular Resistance From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Systemic vascular resistance at Week 12 minus systemic vascular resistance at baseline.
|
Baseline, Week 12
|
Change in the Systemic Vascular Resistance Index From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: baseline, Week 12
|
Change:Systemic vascular resistance index at Week 12 minus systemic vascular resistance index at baseline.
|
baseline, Week 12
|
Change in the Mixed Venous Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Mixed venous oxygen saturation at Week 12 minus mixed venous oxygen saturation at baseline.
|
Baseline, Week 12
|
Change in the Arterial Oxygen Saturation From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Arterial oxygen saturation at Week 12 minus arterial oxygen saturation at baseline.
|
Baseline, Week 12
|
Change in the Arterial Oxygen Partial Pressure From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: baseline, Week 12
|
Change:Arterial oxygen partial pressure at Week 12 minus arterial oxygen partial pressure at baseline.
|
baseline, Week 12
|
Change in the Partial Pressure of Mixed Venous Oxygen From Baseline at Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
Change:Partial pressure of mixed venous oxygen at Week 12 minus partial pressure of mixed venous oxygen at baseline.
|
Baseline, Week 12
|
Changes in the World Health Organization (WHO) Functional Class of Pulmonary Arterial Hypertension From Baseline at Weeks 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 12
|
The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12.
The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).
|
Baseline, Week 12
|
Changes in the BORG Dyspnoea Score From Baseline at Week 8 and Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 8, Week 12
|
Change:BORG dyspnoea score at Week 8 and Week 12 minus BORG dyspnoea score at baseline.
BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum).
The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.
|
Baseline, Week 8, Week 12
|
Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 4, Week 8 and Week 12 in Participants Who Entered the Study From Part I
Time Frame: Baseline, Week 4, Week 8, Week 12
|
Change:Plasma brain natriuretic peptide level at Week 4, Week 8 and Week 12 minus plasma brain natriuretic peptide level at baseline
|
Baseline, Week 4, Week 8, Week 12
|
Change in the 6-minute Walk Distance From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II
Time Frame: Baseline, Week 12
|
Change:6-minute walk distance at Week 12 minus 6-minute walk distance at baseline.
The 6-minute walk distance:Total distance walked during the 6- minute walk test.
|
Baseline, Week 12
|
Change in the World Health Organization (WHO) Functional Class From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II
Time Frame: Baseline, Week 12
|
The cross-tabulation table on the WHO functional classes of pulmonary arterial hypertension at baseline and Week 12.
The WHO functional classes of pulmonary arterial hypertension:Class I (pulmonary arterial hypertension patients with no limitation in physical activity) to Class IV (pulmonary arterial hypertension patients who can not perform a physical activity without any symptoms).
|
Baseline, Week 12
|
Changes in the BORG Dyspnoea Score From Baseline at Week 12 in Participants Who Newly Entered the Study From Part II
Time Frame: Baseline, Week 12
|
Change:BORG dyspnoea score at Week 12 minus BORG dyspnoea score at baseline.
BORG dyspnoea score:Scale 0 (no breathlessness at all) to 10 (maximum).
The score reflected the maximum degree of dyspnoea that the participants experienced at any time during the 6-minute walk distance.
|
Baseline, Week 12
|
Changes in the the Plasma Brain Natriuretic Peptide Level From Baseline at Week 12 in Participants Who Newly Enterd the Study From Part II
Time Frame: Baseline, Week 12
|
Change:Plasma brain natriuretic peptide level at Week 12 minus plasma brain natriuretic peptide level at baseline
|
Baseline, Week 12
|
Maximum Plasma Concentrations (Cmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320
Time Frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
|
Maximum plasma concentrations was calculated from the observed value of plasma concentrations in each participant
|
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
|
Time to First Occurrence of Maximum Plasma Concentrations (Tmax) of Sildenafil and Sildenafil's Metabolite, UK-103,320
Time Frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
|
Time to first occurrence of maximum plasma concentrations were calculated from the observed value of plasma concentrations in each participant.
|
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
|
The Area Under the Curve (AUC) From Time 0 to Time 8 Hour of Sildenafil and Sildenafil's Metabolite, UK-103,320
Time Frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
|
The area under the curve from time 0 to time 8 hour was calculated from area under the curve in each perticipant on the date of blood sampling using the linear/log trapezoidal rule
|
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
|
The Average Plasma Concentration (Css,av) of Sildenafil at Steady State
Time Frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
|
The average plasma concentration of sildenafil at steady state was calculated from the area under the curve from time 0 to 8 hour/dosing interval (8 hours).
|
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
|
The Average Plasma Trough Concentration (Ctrough) of Sildenafil
Time Frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
|
The average plasma trough concentration of sildenafil was calculated from the observed value before administration of the drug in each participants.
|
Pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours after dosing
|
Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Time Frame: Baseline up to 1.3 years
|
The total number of participants with laboratory test abnormalities without regard to baseline abnormality.
|
Baseline up to 1.3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2007
Primary Completion (Actual)
February 1, 2009
Study Completion (Actual)
February 1, 2009
Study Registration Dates
First Submitted
March 28, 2007
First Submitted That Met QC Criteria
March 28, 2007
First Posted (Estimate)
March 30, 2007
Study Record Updates
Last Update Posted (Actual)
February 21, 2021
Last Update Submitted That Met QC Criteria
January 28, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Hypertension
- Pulmonary Arterial Hypertension
- Hypertension, Pulmonary
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Sildenafil Citrate
Other Study ID Numbers
- A1481252
- JapicCTI-070381
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
BayerCompletedPrimary HypertensionChina
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
National Taiwan University HospitalUnknownPulmonary HypertensionTaiwan
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
Clinical Trials on sildenafil citrate (UK-92,480)
-
University of ArizonaCompletedVentricular Dysfunction, Left | Hypertension, Pulmonary ArteryUnited States
-
University of PennsylvaniaWalter Reed National Military Medical CenterNot yet recruitingTraumatic Brain Injury
-
Northwestern UniversityCompletedHand Foot Skin ReactionUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
University of Mississippi Medical CenterActive, not recruiting
-
Pfizer's Upjohn has merged with Mylan to form Viatris...No longer availablePulmonary Arterial HypertensionIndia
-
Federal University of São PauloUniversity of Sao PauloCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed